| Literature DB >> 17179983 |
M K Kang1, R H Kim, S J Kim, F K Yip, K-H Shin, G P Dimri, R Christensen, T Han, N-H Park.
Abstract
Bmi-1 is a polycomb group protein that was identified as c-myc cooperating oncogene in murine lymphomagenesis. The current study was undertaken to determine the role of Bmi-1 in human oral carcinogenesis. Bmi-1 protein and RNA expression levels were markedly enhanced in the cells of oral squamous cell carcinomas (OSCC) compared with that of normal human oral keratinocytes (NHOK). Enhanced-Bmi-1 expression was also detected in situ in the archived oral mucosal tissues with cancerous and precancerous histopathology, including that of mild epithelial dysplasia. Thus, Bmi-1 expression occurs at a very early stage in oral carcinogenesis. To determine the biological role of Bmi-1 in cell proliferation, endogenous Bmi-1 was knocked down in actively proliferating SCC4 cells and NHOK by RNA interference. After Bmi-1 knockdown, cell replication was severely retarded. However, the expression of p16(INK4A), a known cellular target of Bmi-1, was not changed in cells with or without Bmi-1 knockdown. Furthermore, Bmi-1 knockdown in HOK-16B-BaP-T cells, in which the p16(INK4A)/pRb pathway was abrogated, led to immediate arrest of replication and loss of viable cells. Thus, our data suggest that Bmi-1 may act through p16(INK4A)-independent pathways to regulate cellular proliferation during oral cancer progression.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17179983 PMCID: PMC2360223 DOI: 10.1038/sj.bjc.6603529
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Bmi-1 immunoreactivity in situ is elevated in the oral epithelium with dysplastic and cancerous histopathology
|
|
|
|
|
|---|---|---|---|
| Normal ( | 1 | Normal oral epithelium | + |
| 2 | Normal oral epithelium | +/− | |
| 3 | Normal oral epithelium | +/− | |
| 4 | Normal oral epithelium | − | |
| 5 | Normal oral epithelium | − | |
| 6 | Normal oral epithelium | +/− | |
| 7 | Normal oral epithelium | +/− | |
| 8 | Normal oral epithelium | − | |
| Dysplasia ( | 1 | Moderate-severe epithelial dysplasia | +++ |
| 2 | Focal keratosis and mild epithelial dysplasia | ++ | |
| 3 | Mild epithelial dysplasia | + | |
| 4 | Moderate-severe epithelial dysplasia | +++ | |
| 5 | Moderate-severe epithelial dysplasia | ++ | |
| 6 | Hyperkeratosis and mild epithelial dysplasia | ++ | |
| 7 | Severe epithelial dysplasia | +++ | |
| 8 | Mild epithelial dysplasia | ++ | |
| 9 | Severe epithelial dysplasia | +++ | |
| HNSCC ( | 1 | Moderately differentiated squamous cell carcinoma | ++ |
| 2 | Moderately well differentiated squamous cell carcinoma | ++ | |
| 3 | Superficial moderately differentiated squamous cell carcinoma | +++ | |
| 4 | Poorly differentiated squamous cell carcinoma | ++ | |
| 5 | Moderately differentiated squamous cell carcinoma | + | |
| 6 | Well-differentiated squamous cell carcinoma | + | |
| 7 | Well-differentiated squamous cell carcinoma | + | |
| 8 | Moderately differentiated squamous cell carcinoma | ++ | |
| 9 | Well-differentiated squamous cell carcinoma | +++ | |
| 10 | Moderately differentiated squamous cell carcinoma | +++ |
The level of Bmi-1 immunostaining per each specimen was scored as negative (−), barely detectable (+/−), weak (+), moderate (++), or strong (+++) by an oral pathologist, noting the level of chromogenic development after addition of the DAB substrate. The scoring was confirmed blindly by an individual without prior knowledge or understanding of the nature of the tissue specimens.
Bmi-1 in normal oral epithelium was limited to the basal cell layer (Figure 1C).
Bmi-1 staining in the dysplastic and the OSCC samples was homogenously detected in most of the epithelial layers including stratum basale, spinosum, and granulosum (Figure 1C).
Figure 1Bmi-1 is overexpressed in the cancer cells derived from OSCC. (A) Endogenous Bmi-1 expression level was compared by semi-quantitative RT–PCR in NHOK (01–4 and 05–1) and nine cancer cell lines including seven OSCC cell lines. Glyceraldehyde-3-phosphate dehydrogenase was amplified as a loading control. (B) Western blotting was performed to compare the Bmi-1 protein expression levels in NHOK and OSCC cells. HOK/Bmi-1, overexpressing exogenous Bmi-1 (Kim ), was included as a positive control for Bmi-1 expression. In the same samples, we probed for the level of p16INK4A to determine whether aberrant Bmi-1 expression correlated with downregulation of p16INK4A. β-actin was used as a loading control. (C) In situ immunohistochemistry was performed with oral mucosal tissue specimens showing the histological features of normal (n=8), dysplasia (n=9), and OSCC (n=10). The representative examples of histology (left panel, haematoxylin–eosin staining) and the Bmi-1 staining (right panel) are shown in this figure. Bmi-1 expression was detected by DAB staining (brown color). As negative controls, we included normal and OSCC specimens subjected to the staining procedure in the absence of specific Bmi-1 antibody (-Bmi-1 Ab). The images were captured with original magnification of × 100. (D) NHOK (a–c) and SCC4 (d–f) cells were fixed, permeabilised, and stained for Bmi-1 by indirect immunoperoxidase method. Bar=100 μm.
The OSCC cell lines and the status of Bmi-1, p16INK4A, p53, and HPV infection
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| BaP-T | gingiva | − | + | Targeted by E6 | +/type 16 |
| SCC4 | tongue | + | + | mutant | − |
| SCC9 | tongue | + | − | − | − |
| SCC15 | tongue | + | − | − | − |
| HEp-2 | larynx | + | + | Targeted by E6 | +/type 18 |
| 1483 | oral | + | + | Targeted by E6 | +/type 18 |
| FaDu | pharynx | + | + | Mutant | − |
| Tu139 | larynx | + | − | Mutant | − |
| RKO | colorectum | + | − | wild-type | − |
| HeLa | cervix | + | + | Targeted by E6 | +/type 18 |
Bmi-1 overexpression was determined based on the RT–PCR and Western blotting results (Figure 1). Positive indicates enhanced expression compared with the baseline (negative) expression level found in the NHOK cultures.
p16INK4A expression status is based on the Western blotting results (Figure 1B).
Tumourigenic counterpart of NHOK (Park ).
Purchased from American Type Culture Collection. The protein expression patterns for these cell lines were based on Munro .
Gift of P. Sacks (Univ. Texas, Houston, TX, USA).
Gift of G. Clayman (Univ. Texas, Houston, TX, USA).
Gift of M. Kastan (Johns Hopkins, Baltimore, MD, USA).
Figure 2Bmi-1 gene is not amplified in OSCC. Genomic DNAs from five different NHOK strains, two NHOF strains, and seven cancer cell lines were digested with EcoR I and Hind III and transferred for probing. Radiolabelled probes synthesised from Bmi-1 or GAPDH cDNA were hybridised sequentially onto the membrane. The phosphometric intensities were plotted as the ratio of Bmi-1 to GAPDH. The lack of statistical difference (P>0.05) in the levels of Bmi-1 radioactive signals was determined by unpaired T-test (one-ways ANOVA) between the NHOK and the cancer groups.
Figure 3Inhibition of endogenous Bmi-1 causes replication arrest in SCC4 cells. (A) Rapidly proliferating SCC4 cells were infected with LV-GFP or LV-Bmi-1i. After 3 or 10 days, the images were obtained for GFP revealing those cells that were originally infected by the viral vectors. Original magnification, × 100. (B) Three days after infection of NHOK (05-10) and SCC4 cells with LV-GFP or LV-Bmi-1i, the level of Bmi-1 transcript was measured by semi-quantitative RT–PCR. The extent of Bmi-1 knockdown by LV-Bmi-1i was quantitated by Scion Image software against those of GAPDH amplification.
Figure 4Inhibition of endogenous Bmi-1 causes premature senescence in NHOK. (A) Rapidly proliferating NHOK (05-10) was infected with LV-GFP or LV-Bmi-1i. Phase contrast photographs, SA β-Gal staining, and GFP fluorescence were obtained 10 days after virus infection. Original magnification, × 100. (B) Proliferation kinetics of NHOK infected with LV-GFP or LV-Bmi-1i was determined and plotted against time in culture. (C) NHOK cultures were harvested at 10 days after infection with LV-GFP or LV-Bmi-1i, and the expression levels of GPR1, Cyc2A, MMP-1, and MMP-3 were determined by semi-quantitative RT–PCR. The band intensities were quantitated and plotted by Scion Image software against those of GAPDH amplification. (D) NHOK (05-10) and SCC4 cells infected with LV-GFP or LV-Bmi-1i were harvested at 10 days after infection, and Western blotting was performed with 100 μg WCE for p16INK4A. CDK4 was detected as a loading control.
Figure 5Inhibition of endogenous Bmi-1 led to effective loss of viability in BaP-T cells. Rapidly proliferating BaP-T cells were infected with LV-GFP (A), LV-hTERTi (B), LV-Bmi-1i (C), or LV-Cont (D). (A–C) The infected cells were labelled with green fluorescence owing to the GFP expression from the pLL3.7 parental lentiviral vector and shown along with the phase contrast view after 1 day or 8 days post-infection. The cells infected with LV-GFP were passaged owing to reaching confluence after 3–4 days, whereas those infected with LV-Bmi-1i or LV-hTERTi were maintained in the same dish without passaging for the period of observation. (D) In another experiment, BaP-T cells were infected with LV-GFP or LV-Cont. and maintained in parallel for 9 days and photographed. In this experiment, no notable differences in cellular morphology, replication capacity, or viability were noted between the two groups. Bar=200 μm.
Figure 6Effective loss of viability in BaP-T cells infected with LV-Bmi-1i or LV-hTERTi. Viable BaP-T cells infected with LV-GFP, LV-Bmi-1, or LV-hTERTi shown in Figure 5 were quantitated and plotted against period of culture. The total numbers of fluorescence-labelled adherent cells were determined at 3, 5, 6, 8, and 10 days post-infection.